Kristie L. Kahl

“With more potent agents, can we actually cure patients [with prostate cancer]? I'm not so sure about that…because of heterogeneity,” said an expert from NewYork-Presbyterian – Weill Cornell Medical Center in New York City. “So we'll see. But I think with combinations, maybe someday we're going to be able to get there.”

First results from the RADICALS-HD trial demonstrated improved metastasis-free survival with 2 years of androgen-deprivation therapy (ADT) plus radiotherapy in men with prostate cancer.

The risk for disease progression or death was reduced by 27% with the addition of cabozantinib to nivolumab plus ipilimumab in patients with previously untreated renal cell carcinoma.

Tucatinib as monotherapy and in combination with trastuzumab supported further investigation of the regimens in patients with metastatic HER2-positive colorectal cancer.

Neoadjuvant treatment with cemiplimab led to near or complete disappearance of cutaneous squamous cell carcinoma in almost 64% of patients set to undergo surgery.

Overall survival remained durable in patients with metastatic non–small cell lung cancer when tremelimumab was added to durvalumab plus chemotherapy in the frontline setting.

Patients with localized recall cell carcinoma did not have improved disease-free survival with adjuvant nivolumab plus ipilimumab vs placebo.

Results from the LEAP-002 trial revealed extended median overall survival with lenvatinib monotherapy in patients with unresectable hepatocullar carcinoma.

The addition of abemaciclib vs standard-of-care chemotherapy to trastuzumab numerically improved overall survival in women with hormone receptor–positive, HER2-positive advanced breast cancer.

Findings provided rationale to limit air pollution and highlighted the need for molecularly targeted lung cancer prevention due to particulate matter being revealed as a mechanistic driver for EGFR-positive NSCLC.

After 7 years of follow-up, results from the phase 3 SOLO1/GOG-3004 trial support maintenance olaparib to achieve long-term remission in women with newly diagnosed advanced ovarian cancer.

The final analysis of the PAOLA-1/ENGOT-ov25 trial confirmed the benefit of olaparib plus bevacizumab as maintenance therapy following frontline treatment in women with HRD-positive advanced ovarian cancer.

The GARNET trial expansion cohorts showed durable antitumor activity across multiple populations of patients treated with dostarlimab in advanced endometrial cancer.

Results from a cohort of the TAPUR study showed that the combination of cobimetinib plus vemurafenib demonstrated antitumor activity among patients with BRAF mutations who are not otherwise eligible for treatment with other FDA-approved therapies.

The KRAS G12C inhibitor adagrasib demonstrated an objective response rate of 43% and disease control rate of 80% among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

Nimotuzumab plus gemcitabine improved overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct.

The addition of an immune checkpoint inhibitor to CG0070 induced a complete response rate of 88.9% among 18 patients in the phase 2 CORE1 trial.

Genetic determinants of PSA proved to robustly predict prostate cancer diagnoses and improve the detection of aggressive disease; however, larger and more diverse studies are still required.

The time-limited combination of ibrutinib plus chemoimmunotherapy in younger fit patients with chronic lymphocytic leukemia increased the rate of complete responses with bone marrow undetectable minimal residual disease, regardless of IGHV mutation, according to long-term follow-up data.

Among patients with newly diagnosed multiple myeloma, 80% of a study cohort reached MRD negativity following treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone.

The infusion of E-Coli- and Erwinia-derived asparaginase therapies combined with chemotherapy appeared to be well tolerated with biological efficacy in patients with acute lymphoblastic leukemia under the age of 55, providing an additional option for patients for whom further asparagine treatment is contraindicated due to toxicity.

Data presented at 2021 ASH indicate that 2-year progression-free survival rates were improved when ibrutinib was added to rituximab plus mini-CHOP in an elderly cohort of patients with previously untreated diffuse large B-cell lymphoma.

The combination of daratumumab with bortezomib, cyclophosphamide, and dexamethasone continued to improve hematologic and organ responses after 18 months of follow-up.

Patients with hormone receptor-positive, HER2-negative early breast cancer did not see a benefit when adjuvant palbociclib was added to standard endocrine therapy.

Patients with BCG-unresponsive non-muscle invasive bladder cancer may benefit from treatment with avelumab and BCG induction therapy

Investigators believe the use of biomarkers can determine the results of de-escalated neoadjuvant T-DM1 in HR-positive/HER2-positive early breast cancer.

Treatment with sunitinib resulted in improved efficacy results in the FIRSTMAPPP trial for patients with malignant pheochromocytoma and paraganglioma.

Dr. Christopher Lieu shares his insights into gaps in care in the adjuvant setting in colorectal cancer.

An expert in CRC describes key findings from clinical trials related to personalized detection of molecular recurrence in early stage CRC.

Javier L. Munoz, MD, MS, FACP, discusses how the sequencing of therapies has changed in the last year.